AstraZeneca Brilinta Met Primary Endpoint in Phase Three Stroke Trial

AstraZeneca PLC (AZN.LN) said Monday that its drug Brilinta met the primary endpoint in a phase three trial for stroke prevention.
The British pharmaceutical major said high-level results from the phase three THALES trial showed Brilinta used twice daily with aspirin reached a statistically significant reduction in the risk of the primary composite endpoint of stroke and death.
“Results of the Phase three THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack,” Executive Vice President of BioPharmaceuticals R&D Mene Pangalos said.

https://www.marketscreener.com/ASTRAZENECA-4000930/news/AstraZeneca-Brilinta-Met-Primary-Endpoint-in-Phase-Three-Stroke-Trial-29894260/